ICLUSIG will be listed for the treatment of the following patients:
Chronic Myeloid Leukaemia (CML) patients who are resistant or intolerant to both nilotinib and dasatinib
CML patients who are expressing the T315I mutation after prior TKI therapy
Philadelphia positive Acute Lymphoblastic Leukaemia (Ph+ ALL) patients who are expressing the T315I mutation after prior therapy with chemotherapy (with or without a TKI)
The Authority Required listing will commence from 1st November. For more information regarding the PBS listing please refer to the PBS website http://www.pbs.gov.au/pbs/home
As a result of the PBS listing the current ICLUSIG Access Program (IAP) will close prior to the effective listing date. Existing PBS eligible patients on the program will transition to PBS reimbursed drug at the listing date. The final date for supply of ICLUSIG to current registered IAP patients will be on Friday 16th October.
A revised IAP will be offered to Australian patients with Ph+ ALL who are not expressing the T315I mutation. Access under this program will be on the basis of a co-payment for the initial four bottles of supply.
For more information regarding the PBS listing or for information on the Access Program please contact Elwyn Rayson of STA vi email: email@example.com or call the STA Customer Service Team on 1300 798 820.
ICLUSIG is a trademark of ARIAD Pharmaceuticals, Inc.
ICLUSIG is under licence from ARIAD Pharmaceuticals, Inc.